HOME >> BIOLOGY >> NEWS
Optimizing cell therapy against tumors is a balancing ACT

EDITORS' PICK

Adoptive cell transfer (ACT) therapy is used to treat patients with metastatic solid tumors. ACT involves the removal of some of the patient's cancer cells, and some of their immune T cells. When the cells are mixed together, specific parts of the cancer cells that stimulate the T cells to cause an immune attack can be identified. The T cells get expanded and re-infused into the patient to mount an immunological, anti-cancer response against the tumors. One of the challenges faced is selecting the appropriate T cells with proper antigen specificity.

In a new study appearing in the June 1 print issue of The Journal of Clinical Investigation, Nicholas Restifo and colleagues identified which cells are optimal for treating large, vascularized, established tumors. The authors use a mouse model that mimics the human clinical situation. They find that phenotypic and functional qualities of T cells are associated with the ability of ACT to cause regression of large, established melanomas. Seemingly paradoxical, nave and early effector T cells are more effective for tumor treatment than more differentiated T cells.

In an accompanying commentary, Daniel Speiser and Pedro Romero write, "optimal therapeutic efficacy may depend on different T cell selection and preparation strategies" and these findings indicate that a pragmatic strategy for ACT is to keep the in vitro T cell expansion phase as short as possible to keep them nave. These findings are important for development of improved adoptive immunotherapy approaches for treating tumors and established infectious diseases.


'"/>

Contact: Stacie Bloom
press_releases@the-jci.org
212 342-4159
Journal of Clinical Investigation
1-Jun-2005


Page: 1

Related biology news :

1. Testosterone replacement therapy: How safe for aging men?
2. Progesterone therapy and preterm birth: More evidence helps identify women who can benefit
3. Aggressive therapy best for certain AML patients
4. Under magnetic force, nanoparticles may deliver gene therapy
5. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
6. Stem cell therapy rescues motor neurons in ALS model
7. Study identifies new gene therapy tools for inherited blindness
8. Breast cancer and hormone therapy -- A looking-glass mirror?
9. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
10. Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer
11. Scientists follow familiar TRAIL to new cancer therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/18/2020)... ... July 16, 2020 , ... ... effectiveness of the Invictus Medical Neoasis™ active noise control device to attenuate typical ... that the Neoasis™ device attenuated the alarm sounds from patient monitors, ventilators and ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. ... of Neihulizumab, a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), ... Dr. Paul J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, ...
(Date:6/28/2020)... ... 2020 , ... In an upcoming episode scheduled for the fall of 2020, ... solutions (POCT). Check local listings for more info. , Today, the majority of testing ... to labs throughout the country. Results are then available several days later. Now, in ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... SHREWSBURY, Mass. (PRWEB) , ... July 29, 2020 ... ... clad wire that can combine up to three different materials for use with ... can combine up to three materials to meet specific design requirements, performance, and ...
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from Reed Tech , Gary ... in a one hour live webinar on Thursday, August 13, 2020 at ... drugs and medical devices. Specifically, for medical devices, the NMPA has departments dealing with ...
(Date:7/10/2020)... ... July 08, 2020 , ... Bode Technology, ... of laboratory operations through its COVID-19 testing service, Bode-CARES . Bode-CARES combines ... Bode-CARES provides a turnkey solution that includes a comprehensive collection and ...
(Date:7/7/2020)... ... July 06, 2020 , ... Bio-IT World ... Eli Lilly, Bristol-Myers Squibb, the University of Chicago, Massachusetts General Hospital, Mission: Cure, ... an elite awards program, highlighting outstanding examples of how technology innovations and strategic ...
Breaking Biology Technology:
Cached News: